Table 1. Patient-disease and transplant-related characteristics (N-143).

Variable	Value	Total N (%)
Age at alloHCT	Median and range	18y (3-51y).
White blood cells at diagnosis	Median and range x10E9/L	35 (2-7)
Gender	Female Male	105(73%) 38(26.5%)
Adults/Pediatrics	Adult pediatric	67(47%) 76(33%)
ALL subtype (T-cell/B-cell)	T-ALL B-ALL	46(33.5%) 95(66.5%)
Philadelphia by RT-PCR	Positive	34(24%)
Disease risk	High standard	48(34%) 95(66%)
Testicular boost	Yes	67(47%)
Disease status at alloHCT	CR1 ≥ CR2	63 (44%) 80 (56%)
Post all-HCT molecular only relapse by RT-PCR	Yes	2(1.3%)
Post alloHCT isolated CNS relapse	Yes	1(6.6%)
Conditioning regimen	Myeloablative Reduced Intensity	131(91.6%) 12(8.4%)
Thiotepa containing conditioning	Yes	6(4%)
Stem Cell Source	Blood graft	123(86%)
aGVHD	Yes	74(45%)
cGVHD	Yes	69(41%)
Disease status at last follow up	Remission	128(90%)
Patient status at last follow up	Alive	109(76%)